Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a …
Shareholders of Regulus Therapeutics Inc (NASDAQ:RGLS) are having a rough day after the drug maker revealed the termination of two clinical programs, as well …
Today was an explosive day in the biotech-verse as CymaBay Therapeutics Inc (NASDAQ:CBAY) shot up on back of H.C.
Pulmatrix Inc (NASDAQ:PULM) shares are trading sharply down by 26% after the company announced that it had signed a definitive agreement with several …
Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) tumbled 11% today, following the news that the company had received written communication from the FDA requesting additional safety analyses …
Relypsa Inc (NASDAQ:RLYP) is up 6% after the company announced positive results from a pre-specified exploratory analysis of a Phase 3 trial of …
Analysts separately explain why they are bullish on both Celgene Corporation (NASDAQ:CELG) and Regulus Therapeutics Inc (NASDAQ:RGLS) as Celgene works to expand the …
Needham’s healthcare analyst Alan Carr weighted in today on the pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) and San Diego biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS), after …
In a research report released Monday, Deutsche Bank analyst Alethia Young maintained a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) with a $30 price target, …
